Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.
AffiliationDepartment of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractPURPOSE OF REVIEW: A beneficial role for palliative chemotherapy in patients with advanced non-small cell lung cancer and a good performance status (ECOG 0 or 1) is now well established. In this article, we focus on the available literature for patients with a PS of 2, in whom a role for chemotherapy has yet to be defined. RECENT FINDINGS: In the past, the results of randomized trials of comparative standard platinum-based combination chemotherapy regimens have demonstrated inferior survival rates in PS 2 patients compared with those with PS 0 or 1. Consequently, a general view has emerged that the side effects of treatment outweigh the benefits, and chemotherapy has not been recommended as a standard of care. Although few studies have been designed specifically for PS 2 patients, gemcitabine, vinorelbine or taxane monotherapy, dose-attenuated platinum combination regimens, and epidermal growth factor receptor inhibitors may provide a clinical benefit with less toxicity. For example, although the median survival of PS 2 patients treated with best supportive care is 2-3 months, chemotherapy regimens are associated with median survivals ranging from 4 to 6 months. These data provide encouragement to revisit the role of chemotherapy in this group of patients. SUMMARY: There is potential with cytotoxic treatment to improve the palliative options for PS 2 patients with advanced non-small cell lung cancer. Further trials designed specifically for PS 2 patients that include measurement of symptoms, quality of life, and survival and toxicity are required to define the most active but least toxic regimens.
CitationChemotherapy for advanced non-small cell lung cancer patients with performance status 2. 2005, 17 (2):135-9 Curr Opin Oncol
JournalCurrent Opinion in Oncology
- Treatment of locally advanced non-small cell lung cancer in the elderly.
- Authors: Gridelli C, Maione P, Rossi A, Ciardiello F, Raben D
- Issue date: 2005 Mar
- Targeted therapies in lung cancer.
- Authors: Pirker R, Filipits M
- Issue date: 2009
- Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
- Authors: Gridelli C
- Issue date: 2002 Nov
- Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
- Authors: Langer CJ
- Issue date: 2004 Mar 1
- Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
- Authors: Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
- Issue date: 2005 Dec